Evidence map›Paper›PMID 38674115›Full record

ArticleInternational journal of molecular sciences2024

Imbalance between Actin Isoforms Contributes to Tumour Progression in Taxol-Resistant Triple-Negative Breast Cancer Cells.

Vera Dugina, Maria Vasileva, Natalia Khromova, Svetlana Vinokurova, Galina Shagieva, Ekaterina Mikheeva, Aigul Galembikova, Pavel Dunaev, Dmitry Kudlay, Sergei Boichuk and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Localization and Biological Activities of Bioflavonoids fromInternational journal of molecular sciences · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Vera DuginaA.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.
Maria VasilevaScientific Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Natalia KhromovaScientific Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0001-8348-6760
Svetlana VinokurovaScientific Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0003-1615-3928
Galina ShagievaA.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.
Ekaterina MikheevaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Aigul GalembikovaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-0293-2974
Pavel DunaevDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-5449-4435
Dmitry KudlayDepartment of Pharmacology, The I. M. Sechenov First Moscow State Medical University (The Sechenov University), Moscow 119991, Russia.ORCID 0000-0003-1878-4467
Sergei BoichukDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0003-2415-1084
Pavel KopninScientific Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Kazan State Medical University · RULomonosov Moscow State University · RUSechenov University · RU

Funding

Russian Scientific Foundation 23-15-00433
6 · The paper itself

Abstract

The widespread occurrence of breast cancer and its propensity to develop drug resistance highlight the need for a comprehensive understanding of the molecular mechanisms involved. This study investigates the intricate pathways associated with secondary resistance to taxol in triple-negative breast cancer (TNBC) cells, with a particular focus on the changes observed in the cytoplasmic actin isoforms. By studying a taxol-resistant TNBC cell line, we revealed a shift between actin isoforms towards γ-actin predominance, accompanied by increased motility and invasive properties. This was associated with altered tubulin isotype expression and reorganisation of the microtubule system. In addition, we have shown that taxol-resistant TNBC cells underwent epithelial-to-mesenchymal transition (EMT), as evidenced by Twist1-mediated downregulation of E-cadherin expression and increased nuclear translocation of β-catenin. The RNA profiling analysis revealed that taxol-resistant cells exhibited significantly increased positive regulation of cell migration, hormone response, cell-substrate adhesion, and actin filament-based processes compared with naïve TNBC cells. Notably, taxol-resistant cells exhibited a reduced proliferation rate, which was associated with an increased invasiveness in vitro and in vivo, revealing a complex interplay between proliferative and metastatic potential. This study suggests that prolonged exposure to taxol and acquisition of taxol resistance may lead to pro-metastatic changes in the TNBC cell line.

Indexed as

ActinsDisease ProgressionDrug Resistance, NeoplasmPaclitaxelProtein IsoformsTriple Negative Breast NeoplasmsAnimalsAntineoplastic Agents, PhytogenicCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMiceActinsAntineoplastic Agents, PhytogenicPaclitaxelProtein Isoformsactin isoformsbreast cancerEMTmicrotubule reorganisationpro-metastatic changestaxol resistance

Identifiers

PMID38674115
PMCPMC11049934
OpenAlexW4395000479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.